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We demonstrated that inhibition of neutral endopeptidase (NEP), a protease that degrades vaso- and neuroactive peptides,
improves vascular and neural function in diabetic animal models. In this study we explored the role of NEP in neuropathy
related to either insulin-deﬁcient diabetes or diet-induced obesity using NEP deﬁcient (−/−) mice. Initial studies showed that
streptozotocin, in the absence of subsequent hyperglycemia, did not induce nerve conduction slowing or paw thermal hypoalgesia.
Glucose disposal was impaired in both C57Bl/6 and NEP −/− mice fed a high fat diet. Thermal hypoalgesia and nerve conduction
slowing were present in both streptozotocin-diabetic and high fat fed C57Bl/6 mice but not in NEP −/− mice exposed to either
streptozotocin-induced diabetes or a high fat diet. These studies suggest that streptozotocin does not induce neurotoxicity in mice
and that NEP plays a role in regulating nerve function in insulin-deﬁcient diabetes and diet-induced obesity.
Copyright © 2009 Eric Davidson et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Peripheral neuropathy aﬀects patients with diabetes as well
as patients that have impaired glucose tolerance and are
considered to be prediabetic [1–5]. Diabetes is the most
common cause of peripheral neuropathy [5]. However,
about a third of neuropathy patients have no identiﬁable
etiology although 40% of these patients have impaired
glucose tolerance [5]. Diabetic neuropathy is considered to
be a multifactorial disease arising from interactions between
abnormal metabolic activity and impaired vascular function
[2, 6, 7]. The etiology of peripheral neuropathy in patients
with impaired glucose tolerance is less clear. However, it has
been demonstrated that metabolic improvement resulting
from aggressive therapy to normalize glucose, hypertension,
and hyperlipidemia reduced neuropathic pain in this patient
cohort [5].
Our studies have focused on the role of vascular dys-
function in peripheral neuropathy using diabetic animal
models as well as animal models of obesity [8–10]. In both
type 1 and type 2 diabetic rats we have demonstrated that
impaired vascular reactivity precedes the development of
nerve dysfunction as identiﬁed by reduced nerve conduction
velocity [8–11]. Recently we have found that expression of
neutral endopeptidase in epineurial arterioles of the sciatic
nerve is increased in diabetes and that treating diabetic
animal models with AVE7688, a vasopeptidase inhibitor,
improves vascular and neural function [12, 13]. Further-
more,ithasbeendemonstratedthatvasopeptidaseinhibitors
are neuroprotective and prevent nephropathy in diabetic
rats [14–17]. Vasopeptidase inhibitors are a new class of
drug that simultaneously inhibits neutral endopeptidase
and angiotensin converting enzyme activity [18]. Neutral
e n d o p e p t i d a s ed e g r a d e san u m b e ro fv a s o a c t i v ep e p t i d e s
including natriuretic peptides, adrenomedullin, bradykinin,
and calcitonin gene-related peptide [19]. Neutral endopep-
tidase is found in many tissues including vascular and renal
tissues and its activity is increased by fatty acids and glucose2 Experimental Diabetes Research
in human microvascular cells [20–24]. In the peripheral
nervous system neutral endopeptidase is located in Schwann
cell membranes surrounding dorsal root ganglion cells and
nerve ﬁbers [25, 26]. In the central nervous system neutral
endopeptidase is associated with neuronal tissue rather than
astrocytes [25]. High levels of the enzyme are present in all
neonatal and early postnatal Schwann cells as myelination
proceeds it is gradually suppressed in the majority of cells
that form myelin but retained in nonmyelin forming cells
in the adult animal [26]. Kioussi et al. found that following
axonal damage neutral endopeptidase is re-expressed distal
to the injury [26]. These authors suggest that neutral
endopeptidase could play a role in axonal regeneration
[26]. To further explore the role of neutral endopeptidase
in peripheral neuropathy induced by diabetes or obesity
we performed studies using neutral endopeptidase deﬁcient
mice. We hypothesized that because diabetes/obesity would
not be able to increase neutral endopeptidase in these mice
that nerve function would be protected in diabetic or high
fat fed neutral endopeptidase deﬁcient mice. Sciatic nerve
conduction velocity slowing and prolonged paw thermal
response latency were used as indices of large and small ﬁber
dysfunction, respectively, in both the streptozotocin-treated
andhighfatfedmousemodelsofperipheralneuropathyafter
demonstrating that these disorders were not a consequence
of direct streptozotocin-induced neurotoxicity.
2.MaterialsandMethods
Unless stated otherwise all chemicals used in these studies
were obtained from Sigma Chemical Co. (St. Louis, MO).
2.1. Animals. C57Bl/6 wild type mice were purchased from
JacksonLaboratoriesandSwissWebstermicewerepurchased
fromHarlanlaboratories.Breedingpairsofneutralendopep-
tidase deﬁcient (NEP −/−)m i c ew e r ep r o v i d e db yL ue t
al. and are on the C57Bl/6 background [27]. These mice
have been bred and a colony created at the Veterans Aﬀairs
Medical Center, Iowa City, Iowa. The C57Bl/6 and NEP −/−
micewereagedmatchedforthestudies.Deﬁciencyofneutral
endopeptidase activity was conﬁrmed in the mice used for
these studies by measuring the speciﬁc activity of neutral
endopeptidase in kidney homogenates using the method
described by Ayoub and Melzig [28] with modiﬁcation.
Activity of neutral endopeptidase in kidney from C57Bl/6
and NEP −/− mice was 2.32 ± 0.11 and 0.18 ± 0.06∗ μM
7-amido-3-methylcoumarin (AMC)/min/μgprotein,respec-
tively (∗P<. 001 versus C57Bl/6 by unpaired t-test).
Mice were housed in a certiﬁed animal care facility
and food (Harlan Teklad, #7001, Madison, WI) and water
were provided ad libitum. Adequate measures were taken
to minimize pain or discomfort and all of the experiments
were conducted in accordance with international standards
on animal welfare and were compliant with all institutional
andNationalResearchCouncil’sguidelinesforuseofanimals
(ACURF protocol 0802033).
An initial study was performed to address whether
streptozotocin causes direct neurotoxicity, independent of
inducing insulin deﬁciency and hyperglycemia. This study
was performed by two diﬀerent laboratories (Yorek and
Calcutt) using two diﬀerent strains of mice. C57Bl/6 and
SwissWebstermiceat12weeksofageweredividedintothree
groups. The ﬁrst group was treated with vehicle and served
as the control group. The second group was treated with
streptozotocin (150mg/kg i.p. in saline as a single dose to the
C57 Bl/6 mice or 90mg/kg i.p. on two consecutive days to
the Swiss Webster mice) to induce diabetes. The third group
was treated with 3-O-methylglucose (5.5mmol/kg body wt,
i.p.) approximately one minute prior to each streptozotocin
injection to prevent the eﬀects of the streptozotocin on
the pancreatic β cells [29, 30]. Diabetes was veriﬁed 96
hours later by evaluating blood glucose levels with the use
of glucose dehydrogenase reagent strips (Accu-Chek, Roche
Diagnostics, Indianapolis, IN). Nerve function was assessed
after eight (Swiss Webster) or twelve (C57Bl/6) weeks of
diabetes.
For the study examining the inﬂuence of deletion of
the NEP gene C57Bl/6 and NEP −/− mice at 12 weeks
of age were divided into three groups. One group was
fed the standard chow diet. A second group was fed a
diet containing 60%kcal as fat (D12492, Research Diets,
New Brunswick, NJ). The third group was treated with
streptozotocin (150mg/kg i.p. in saline) to induce diabetes.
Mice having blood glucose level of 300mg/dL (16.7mM)
or greater were considered to be diabetic. The experimental
period lasted for 12 weeks.
2.2. Glucose Tolerance. Prior to behavioral and nerve con-
duction studies control and high fat fed mice were fasted
overnight for study of glucose utilization. Mice were injected
with a saline solution containing 2g/kg glucose, i.p. Imme-
diately prior to the glucose injection and for 120 minutes
afterwards blood samples were taken to measure circulating
glucose levels.
2.3. Thermal Nociceptive Response. The day before the
terminal studies thermal nociceptive response in the hind-
paw was measured using the Hargreaves method with
instrumentation provided by IITC Life Science; Woodland
Hills, CA (model 390G) or UARD (San Diego). The test
was performed when possible in a blind manner. Thermal
nociceptive responses were measured by placing the mouse
in the observation chamber on top of the thermal testing
apparatus and allowing it to acclimate to the warmed
glass surface (30
◦C) and surroundings for a period of
15 minutes. The mobile heat source was maneuvered so
that it was under the heal of the hindpaw and then
activated, a process that activates a timer and locally
warms the glass surface, when the mouse withdrew its
paw, the timer, and the heat source was turned oﬀ [31].
Following an initial recording, which was discarded, four
measurements were made for each hindpaw, with a rest
period of 5 minutes between each set of measurements.
The mean of the measurements, reported in seconds, was
used as a measure of the thermal nociceptive response
latency.Experimental Diabetes Research 3
2.4. Motor and Sensory Nerve Conduction Velocity. Mice were
anesthetized with Nembutal (75mg/kg, i.p., Abbott Labora-
tories, North Chicago, IL) or isoﬂurane (4% in oxygen) and
nonfasting blood glucose levels determined with the use of
glucose oxidase reagent strips (Lifescan Inc., Milpitas, CA).
Afterwards, motor and sensory nerve conduction velocities
were determined as previously described [12, 13, 32]. Motor
nerve conduction velocity was determined noninvasively
in the sciatic-posterior tibial conducting system [12, 13].
Sensory nerve conduction velocity (SNCV) was determined
using the digital nerve to the second toe as described by
Obrosova et al. [32]. The MNCV and SNCV were reported
in meters per second.
2.5. Data Analysis. The results are presented as mean ± SE.
Comparisons between the groups for body weight, blood
glucose, MNCV, SNCV, and thermal nociception latency
were conducted using a one-way ANOVA and Bonferroni’s
test for multiple comparisons (Prism software; GraphPad,
San Diego, CA). A P-value of less .05 was considered
signiﬁcant.
3. Results
3.1. Streptozotocin Neurotoxicity. There has been a consid-
erable amount of discussion about the possible neurotoxic
eﬀect of streptozotocin and the suitability of streptozotocin-
induced diabetes as an acceptable model for diabetic neu-
ropathy especially in mice when high doses of streptozotocin
are used to induce diabetes. To address this issue we used a
procedure previously used in rats to protect the pancreatic
β cells from streptozotocin toxicity [29, 30]. C57Bl/6 and
Swiss Webster mice treated with 3-O-methylglucose prior to
injection of streptozotocin were normoglycemic and insulin
levels were similar to control mice (Table 1). In contrast,
mice treated with streptozotocin alone developed hyper-
glycemia and circulating insulin levels that were signiﬁcantly
decreased. In addition, diabetic mice developed neuropathy,
as determined by slowing of nerve conduction velocity and
increased response latency to a thermal challenge. Nerve
conduction velocity and thermal nociception were normal
in 3-O-methylglucose/streptozotocin treated mice. These
studies suggest that streptozotocin is not directly neurotoxic
in two mouse strains and that nerve function deﬁcits
are most likely related to the diabetes-like conditions that
develop subsequent to diabetes arising from streptozotocin-
induced pancreatic β cell damage.
3.2. Role of NEP in Diabetic Neuropathy. Data in Table 2
provide background information on the change in body
weight and nonfasting blood glucose level of C57Bl/6 and
NEP −/− mice used in this study. The experimental period
b e g a nw h e nt h em i c ew e r e1 2w e e k so fa g ea n dl a s t e df o r
12 weeks. At 12 weeks of age C57Bl/6 mice weighed about
27g and gained over 4g during the next 12 weeks. C57Bl/6
mice made diabetic at 12 weeks of age did not gain weight
during the experimental period and weighed signiﬁcantly
less and had a greater blood glucose level then control
Table 1: Eﬀect of 3-O-methyl-glucose on Markers for Diabetic
Neuropathy in Streptozotocin-treated C57Bl/6 and Swiss Webster
Mice.
C57Bl/6 Control (10) Diabetic (15)
3-O-methyl-
glucose
(15)
Start weight (g) 25. ± 0.7 26.9 ± 0.4 25.4 ± 0.5
End weight (g) 30.6 ± 1.0 25.7 ± 0.8∗ 29.6 ± 0.5+
Blood glucose
(mg/dL) 175 ± 8 582 ± 6∗ 214 ± 27+
Insulin (pM) 10.6 ± 3.4 0.7 ± 0.3∗ 12.8 ± 3.0+
MNCV (m/sec) 33.6 ± 2.2 21.6 ± 1.2∗ 35.7 ± 1.6+
SNCV 23.2 ± 0.8 18.6 ±0.4∗ 22.8 ± 0.5+
Thermal response
latency (sec) 6.70 ± 0.40 12.08 ± 0.92∗ 7.21 ± 0.27+
Swiss Webster Control (9) Diabetic (9)
3-O-methyl-
glucose
(9)
Start weight (g) 27.8 ± 0.6 29.0 ± 0.7 27.4 ± 0.4
End weight (g) 32.1 ± 1.3 24.6 ± 0.4∗ 32.3 ± 1.0+
Blood glucose
(mg/dL) 182 ± 24 573 ± 27∗ 226 ± 14+
MNCV (m/sec) 47.8 ± 1.2 38.8 ± 1.4∗ 46.4 ± 1.7+
Thermal response
latency week 4
(sec)
5.6 ± 0.4 8.8 ± 0.7∗ 5.0 ± 0.6+
Thermal response
latency week 8
(sec)
4.9 ± 0.4 7.7 ± 0.9∗ 5.8 ± 0.4
Data are presented as the mean ± SEM. ∗P<. 05 compared to control for
the respective group, +P<. 05 compared to diabetic. Parentheses indicate
the number of experimental animals.
Table 2: Weight Change and Blood Glucose Values for C57Bl/6 and
NEP −/− Mice.
C57Bl/6 Control (24) Diabetic (15) High Fat (15)
Start weight (g) 26.8 ± 0.4 26.9 ± 0.4 28.0 ± 0.4
End weight (g) 31.3 ± 0.5 26.4 ± 0.6∗ 42.0 ± 1.6∗
Blood glucose (mg/dL) 174 ± 4 592 ± 16∗ 150 ± 4
NEP −/− Control (16) Diabetic (23) High Fat (17)
Start weight (g) 26.7 ± 0.5 26.4 ± 0.6 24.7 ± 0.6
End weight (g) 31.4 ± 0.7 25.0 ± 0.7∗ 47.6 ± 1.1∗
Blood glucose (mg/dL) 169 ± 6 530 ± 25∗ 184 ± 14
Dataarepresentedasthemean±SEM. ∗P<. 05comparedtocontrolforthe
respective group. Parentheses indicate the number of experimental animals.
mice at 24 weeks of age. C57Bl/6 mice fed a high fat diet
for 12 weeks weighed signiﬁcantly more then control mice
at 24 weeks of age. Neutral endopeptidase deﬁcient mice
at 12 weeks of age weighed about the same as C57Bl/6
mice. Like C57Bl/6 control mice, neutral endopeptidase
deﬁcient mice gained about 4g from 12 to 24 weeks of age.
The induction of diabetes with streptozotocin in neutral4 Experimental Diabetes Research
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Figure 1: Glucose utilization curve for C57Bl/6 (a) and neutral endopeptidase (NEP −/−) deﬁcient mice (b) fed a normal or high fat
containing diet for 12 weeks. Data are the mean ± standard error of the mean. The numbers of animals for each group are indicated in
parenthesis. ∗P<. 05 versus control.
endopeptidase deﬁcient mice was comparable to C57Bl/6
mice. Diabetic neutral endopeptidase deﬁcient mice failed
to gain weight and had signiﬁcantly higher blood glucose
levels than control neutral endopeptidase deﬁcient mice.
Neutral endopeptidase deﬁcient mice fed a high fat diet for
12 weeks weighed signiﬁcantly more than control neutral
endopeptidase deﬁcient mice at 24 weeks of age and their
weight gain was similar to C57Bl/6 mice. Nonfasting blood
glucose level was not increased in C57Bl/6 or neutral
endopeptidase deﬁcient mice fed a high fat diet.
Data in Figure 1 demonstrate that C57Bl/6 and neutral
endopeptidase deﬁcient mice fed a high fat diet had a sig-
niﬁcantly higher fasting blood glucose level than respective
mice fed a normal diet. Glucose clearance was signiﬁcantly
impaired in C57Bl/6 and neutral endopeptidase deﬁcient
mice fed a high fat diet.
After 12 weeks of untreated diabetes or high fat diet
motor and sensory nerve conduction velocity was deter-
mined in C57Bl/6 and neutral endopeptidase deﬁcient mice
and respective controls. Data in Figure 2 demonstrate that
motor and sensory nerve conduction velocity is signiﬁcantly
decreased in diabetic C57Bl/6 mice. In contrast, after 12
weeks of diabetes motor and sensory nerve conduction
velocity in neutral endopeptidase deﬁcient mice is not
signiﬁcantly diﬀerent than control mice and is signiﬁcantly
greater compared to diabetic C57Bl/6 mice. Feeding C57Bl/6
mice but not neutral endopeptidase deﬁcient mice a high
fat diet for 12 weeks caused a signiﬁcant decrease in sensory
nerve conduction velocity. Feeding a high fat diet to C57Bl/6
and neutral endopeptidase deﬁcient mice did not change
motor nerve conduction velocity.
Data in Figure 3 demonstrate that response to a thermal
stimulus to the hindpaw is impaired in C57Bl/6 diabetic and
high fat fed mice compared to control C57Bl/6 mice. Thus,
after 12 weeks of diabetes or high fat diet C57Bl/6 mice are
thermal hypoalgesic. In contrast, thermal responsiveness in
diabetic or high fat fed neutral endopeptidase deﬁcient mice
is not impaired compared to control neutral endopeptidase
deﬁcient mice and is signiﬁcantly more responsive compared
to diabetic or high fat fed C57Bl/6 mice, respectively.
Furthermore, control neutral endopeptidase deﬁcient mice
are more sensitive to a painful stimulus than control C57Bl/6
mice.
4. Discussion
Diabetes is the most common cause of peripheral nerve
damage rendering both diﬀuse damage referred to as
polyneuropathy and focal damage or mononeuropathy [33,
34]. It is now known that painful sensory neuropathy is
also associated with impaired glucose tolerance or metabolic
syndrome [35–38]. Animal studies of the pathophysiologyExperimental Diabetes Research 5
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Figure 2: Motor and sensory nerve conduction velocity for C57Bl/6 (a) and neutral endopeptidase (NEP −/−)d e ﬁ c i e n tm i c e( b ) .S t u d y
groups included mice fed a normal diet for 12 weeks (control), streptozotocin-induced diabetes duration 12 weeks, or fed a high fat
containing diet for 12 weeks. Data are the mean ± standard error of the mean. The numbers of animals for each group are indicated in
parenthesis. ∗P<. 05 versus control, +P<. 05 versus C57Bl/6 mice.
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Figure 3: Thermal response latency in the hindpaw for C57Bl/6
and neutral endopeptidase (NEP −/−) deﬁcient mice. Study
groups included mice fed a normal diet for 12 weeks (control),
streptozotocin-induced diabetes duration 12 weeks, or fed a high
fatcontainingdietfor12weeks.Dataarethemean ±standarderror
of the mean. The numbers of animals for each group are the same
as described in Table 1. ∗P<. 05 versus control C57Bl/6, +P<. 05
C57Bl/6 mice versus NEP −/− mice, respectively.
of diabetic polyneuropathy have provided us with a long list
of mechanisms and possible treatments but these treatments
have generally failed in clinical trials [34]. Thus, at this time
there is no eﬀective therapy for diabetic polyneuropathy.
As described by Zochodne [34], there are likely many
reasons for the disappointing results of these clinical trials
including choice of agent, trial design, and endpoints.
Since the etiology of diabetic polyneuropathy appears to be
multifactorial it seems unlikely that a single intervention will
bebeneﬁcialandamoremultitargetedapproachisnecessary.
My laboratory has focused on the role of microvas-
cular dysfunction in the development and progression of
peripheral nerve disorders. Our studies in both type 1 and
type 2 diabetic rats and rat models of metabolic syndrome
havedemonstratedthatimpairedvascularreactivityprecedes
the development of nerve dysfunction as identiﬁed by
reduced nerve conduction velocity [6, 8–11]. Recently we
have been examining the role of neutral endopeptidase
and the eﬀect of vasopeptidase inhibition in diabetes- and
obesity-induced vascular and neural dysfunction. Neutral
endopeptidase is found in many tissues including vascular,
renal, and neural tissues and its activity is increased by
fatty acids and glucose in human microvascular cells [20–
26]. Interestingly, neutral endopeptidase activity has been
shown to be activated by protein kinase C, which is6 Experimental Diabetes Research
increased in vascular tissues by diabetes [39, 40]. Neutral
endopeptidase degrades vasoactive peptides including natri-
uretic peptides, adrenomedullin, bradykinin, and calcitonin
gene-related peptide [19]. Therefore, use of vasopeptidase
inhibitors, a new class of drug that simultaneously inhibits
neutral endopeptidase and angiotensin converting enzyme
activity, would likely promote expression of vasoactive
peptides by blocking degradation and thus, improving
vascular function. In this regard, vascular conductance in the
femoral artery of streptozotocin-induced diabetic rats was
improved by a vasopeptidase inhibitor [41]. Furthermore,
it has been demonstrated that vasopeptidase inhibitors
are neuroprotective and prevent nephropathy in Zucker
diabetic fatty rats [14–17]. Vasopeptidase inhibitors have
also been reported to decrease matrix metalloproteinases
and AGE accumulation/formation in type 2 diabetes and
improve wound healing [42–44]. In our previous studies we
have demonstrated that treatment of streptozotocin-induced
diabetic rats and Zucker diabetic fatty rats, animal models
for types 1 and 2 diabetes, respectively, with AVE7688, a
vasopeptidase inhibitor, improved slowing of motor and
sensory nerve conduction velocity and vascular impairment
[12, 13]. In the previous studies we have also demonstrated
that treating streptozotocin-induced diabetic rats or Zucker
diabetic fatty rats with Enalapril, an angiotensin converting
enzyme inhibitor, improved nerve and vascular dysfunction
[45, 46]. However, we concluded that AVE7688 treatment
for diabetic neural and vascular complications was more
eﬀective than Enalapril [7].
In order to further investigate the role of neutral
endopeptidase in peripheral nerve dysfunction we examined
the eﬀect of streptozotocin-induced diabetes and diet-
induced obesity on nerve conduction velocity and thermal
response latency in the hindpaw of C57Bl/6 mice and mice
deﬁcient in neutral endopeptidase. The two major ﬁndings
ofthesestudiesarethatstreptozotocinitselfisnotneurotoxic
and that neutral endopeptidase deﬁcient mice are protected
from the slowing of nerve conduction velocity and thermal
hypoalgesiathatoccurinstreptozotocin-induceddiabetic-or
diet-induced obesity-C57Bl/6 mice.
Pabbidi et al. [47] have reported that streptozotocin has
a direct action on neurons and modulates the expression
and function of TRPV1, a nociceptive ion channel that
is responsible for inﬂammatory thermal pain. In stud-
ies performed using dorsal root ganglion neurons they
found that hydrogen peroxide mimicked the eﬀects of
streptozotocin in regard to increasing the expression of
TRPV1. In animal studies they found that some mice
injected with streptozotocin (50–200mg/kg) did not become
hyperglycemicbutexhibited atransient thermalhyperalgesia
using a hot plate test that returned to normal within weeks.
This contrasted with hyperglycemic mice that progressed
from hyperalgesia to hypoalgesia. In our present studies,
mice displayed hypoalgesia 4–12 weeks after injection of
streptozotocin and subsequent induction of diabetes. We
did not examine our mice earlier than 4 weeks of diabetes,
although we have previously reported thermal hypoalgesia
a se a r l ya s2w e e k sa f t e ro n s e to fs t r e p t o z o t o c i n - i n d u c e d
diabetes [48]. Mice treated with 3-O-methylglucose prior
to injection of streptozotocin did not demonstrate signs of
neuropathy, as indicated by slowing of nerve conduction
velocity or altered thermal response latency. We conclude
from our studies that streptozotocin alone is not responsible
forthermalhypoalgesiaornerveconductionslowinginmice.
Our ﬁndings suggest that neutral endopeptidase activity
contributes to peripheral neuropathy observed in type 1
diabetes and diet-induced obesity. Slowing of motor and
sensory nerve conduction velocity is a common feature in
animal models of streptozotocin-induced diabetes [49, 50].
Likewise, it has been demonstrated that C57Bl/6 mice fed
a high fat diet for 16 weeks have motor and sensory nerve
conduction deﬁcits and thermal hypoalgesia [51].
A reason for the normalcy of nerve conduction velocity
in diabetic and obese neutral endopeptidase deﬁcient mice
could be the preservation of vascular function. In diabetic
and obese rats we have demonstrated that treatment with
a vasopeptidase inhibitor prevents vascular dysfunction [12,
13]. This was likely due to protecting vasoactive peptides
from degradation by neutral endopeptidase [12, 13, 52,
53]. Preservation of calcitonin gene-related peptide and
substance P in the dorsal root ganglion of diabetic mice by
nerve growth factor has also been shown to prevent/improve
diabetic sensory neuropathy [54]. Since neutral endopep-
tidase degrades both calcitonin gene-related peptide and
substance P it would be expected that mice deﬁcient in
neutral endopeptidase would maintain higher levels of both
of these neuroactive peptides and perhaps be protected from
neuropathy.
We observed that diabetes- or obesity-induced ther-
mal hypoalgesia of the hindpaw was prevented in neutral
endopeptidase deﬁcient mice. In our studies mice were
diabetic or fed a high fat containing diet for 12 weeks prior
to experimentation. Beiswenger et al. [48] reported that
thermalhypoalgesiadevelopedafteronly2weeksofdiabetes.
Interestingly, they found that a measurable reduction in
immunoreactive epidermal nerve ﬁber density could not
be detected until after 4 weeks of diabetes leading them
to suggest that impaired epidermal nociceptor function
contributes to early diabetes-induced thermal hypoalgesia
prior to the loss of peripheral terminals. We propose that
increased expression of neutral endopeptidase in epidermal
nerve ﬁbers may contribute to epidermal nociceptor dys-
functionbyincreasingdegradationofcalcitoningene-related
peptide and substance P neuroactive peptides involved in
pain perception. Neutral endopeptidase is expressed in
normal skin and is increased in wounds [55]. In normal
skin neutral endopeptidase was localized by immunohisto-
chemistry to keratinocytes of the epidermal basal layer, to
hair follicles, eccrine and sebaceous glands, endothelium of
blood vessels and large nerves [53]. Furthermore, neutral
endopeptidase activity is increased in skin of patients with
diabetic ulcers [56]. It is thought that this may contribute
to deﬁcient neuroinﬂammatory signaling and may impair
wound healing [56]. We have shown that expression of
neutral endopeptidase is increased in epineurial arterioles
of the sciatic nerve in diabetic rats [12, 13]. It remains
to be determined whether expression/activity of neutral
endopeptidase is increased in the epidermis of the footpadExperimental Diabetes Research 7
of diabetic or obese mice and how this relates to changes in
epidermal nerve ﬁber density.
Normal neutral endopeptidase deﬁcient mice were ther-
mal hyperalgesic compared to control C57Bl/6 mice as
determined by latency of withdrawal threshold of the hind-
paw. Increased sensitivity to pain stimulus has previously
been demonstrated in neutral endopeptidase deﬁcient mice
or inhibition of neutral endopeptidase activity [56–58].
It has been shown that neutral endopeptidase knockout
in mice induces hyperalgesia induced by bradykinin in a
model of visceral pain [57]. Bradykinin is also a peptide
degraded by neutral endopeptidase. In studies with human
skin inhibition of neutral endopeptidase facilitated neu-
rogenic inﬂammation and that neutral endopeptidase but
not angiotensin converting enzyme was more important
for degradation of calcitonin gene-related peptide [58].
Using neutral endopeptidase knockout mice the same group
found an increased pain behavior and signs of neurogenic
inﬂammation after soft tissue trauma with and without
nerve injury [59]. It is possible that the diabetic or obese
neutral endopeptidase deﬁcient mice in our studies did not
become thermal hypoalgesic because these mice are more
sensitive to a painful stimulus than wild type mice and this
sensitivity masked any changes to thermal responsiveness in
the hindpaw.
5. Conclusions
Using C57Bl/6 and Swiss Webster mice we found that
streptozotocin alone is not neurotoxic or responsible for
nerve dysfunction associated with streptozotocin-induced
diabetes. These studies also provide additional evidence that
expressionofneutralendopeptidaseplaysaroleinperipheral
neuropathy that accompanies diabetes and/or diet-induced
obesity. Continued investigation into therapeutic means
to manipulate the activity of neutral endopeptidase and
perhapsothermetalloendopeptidasesmayleadtoaneﬀective
treatment for peripheral polyneuropathy.
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